Anal cancer – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Anal cancer

Anal cancer – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Anal cancer is a malignant (cancerous) tumor of either the anal canal or anal verge. Literature suggest some risk factor associated with anal cancer such as HIV infection, Lowered immunity and Smoking.

Classification of Anal cancer:-

Carcinoma in situ is early cancer or precancerous cells. They are only on the surface cells of the anal canal. This also may be called Bowen’s disease.

Squamous cell cancer (carcinoma) forms in the cells that line the anus. This is the most common type of anal cancer.

Adenocarcinomas develop in the glands around the anus.

Skin cancers, including basal cell and melanoma, often are found when they are in advanced stages.

According to Thelansis estimates, Anal cancer epidemiology in year 2020, for the US was about 8,590 new cases (5,900 in women and 2,690 in men) and 1,350 deaths (810 in women and 540 in men).

Competitive landscape of Anal cancer includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Anal cancer across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Anal cancer Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Anal cancer – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No     Asset     Company           Stage

1            Pembrolizumab Merck Sharp & Dohme Corp.      Phase 2

2            MPDL3280A       Roche Pharma AG           Phase 2

3            BMX-001            BioMimetix JV, LLC          Phase 2

4            ADXS11-001       Advaxis, Inc.      Phase 2

5            cetuximab          The Emmes Company, LLC           Phase 2

6            RTX-321              Rubius Therapeutics       Phase 1

7            VGX-3100           Inovio Pharmaceuticals Phase 2"